MARC
Why margin compression is the new reality, and how transparent AI turns operational efficiency into enterprise value
The dental M&A market went through a recalibration that caught many groups by surprise. Interest rates rose. Capital costs spiked. EBITDA multiples that peaked at 8 to 12x in 2022 softened back toward 8x or lower by early 2023.
Many DSOs found themselves in technical breach of loan covenants. Acquisitions paused. Business development teams shrank or disappeared entirely. The focus shifted hard to same-store growth and margin expansion.
AI became the efficiency tool everyone needed. Automated revenue cycle management, smarter patient scheduling, optimized marketing spend. These directly impact EBITDA when they work.
But here's the trap most groups fell into. Most AI tools are black boxes. They generate recommendations that operators can't validate. When trust is low, adoption stalls. When adoption stops, EBITDA stays flat.
Explainable AI changes that equation completely.
🧠 Grab the Dental CMO Co-Pilot GPT and turn chaos into a 90-Day Plan.
The Market Shift That Changed Everything
Before COVID, dental groups traded at EBITDA multiples in the 6 to 10x range according to TUSK Practice Sales analysis. By mid-2022, those multiples surged to 8 to 12x driven by aggressive private equity deployment and PE-backed DSO acquisition activity.
When demand goes up, prices follow. The post-COVID period sparked an unprecedented rush to deploy capital, making 2021 the most intense year for dental M&A on record.
Then inflation hit. The Federal Reserve responded with aggressive interest rate hikes. By early 2023, these conditions delivered a significant blow to the industry, hampering DSO cash flow across the board.
Many groups watched the cost of their credit facilities skyrocket in a short period of time. The pain was immediate. Groups that had been operating smoothly suddenly found themselves in technical breach of loan covenants, forcing them to pause acquisitions while addressing EBITDA margin compression and waiting for interest rates to stabilize.
Brian Colao, Director of Dykema's DSO Industry Group, describes it as a significant recalibration, transitioning from an era of nearly zero-cost capital to high interest rates and now to slowly improving conditions.
Numerous dental groups reduced or eliminated their business development teams entirely, shifting their focus to same-store growth. Many turned to technology to streamline operations, reduce costs, and improve efficiency.
The New Investment Thesis
The era of just aggregating EBITDA is over, according to Preston Brice, Managing Partner of Barclay Hill Partners.
Investors are no longer content with growth through acquisition alone. They now prioritize operational efficiency, same-store growth, and low staff turnover. These outcomes are increasingly driven by unified and modern tech infrastructure.
When Lorri Detrick, President and COO of Riccobene Associates Family Dentistry, led her team through their recent quest for a new private equity partner, she discovered something critical. "Investors are looking for so much more than profitability," she explained.
Riccobene was one of the few large DSOs to secure private equity funding in 2024. Their standardized technology and operating systems provided centralized data, real-time visibility, and operational consistency. That level of transparency not only streamlined the due diligence process but helped them command a stronger valuation.
Tech stack standardization is now the hallmark of a good organization and a value signal to acquirers. In order to drive maximum value, you need integration and organic growth in addition to high-quality teams and proven growth models.
The groups that show resiliency and growth even during challenging economic times will be well-positioned for recapitalization events in 2025 and beyond.
Where AI Fits in the Margin Expansion Playbook
AI and automation allow DSOs to do more with less, and to do it better. Tools like automated insurance posting, AI radiograph analysis, and intelligent call handling help reduce administrative burdens and enhance patient experience.
But there's a trust problem most groups don't talk about publicly.
When an AI system recommends shifting $50,000 from Google Ads to Facebook, can your CMO explain why? When a scheduling algorithm suggests reducing hygiene hours at a specific location, can your operations manager validate the logic?
Most AI tools provide recommendations without showing their work. This creates a credibility gap that slows adoption. Teams don't trust what they can't understand. Projects stall in pilot phases. The promised EBITDA improvements never materialize at scale.
📊 Download the Dental CMO Co-Pilot GPT and ask it, “Where am I leaking the most value right now?”
How Explainable AI Breaks the Trust Barrier
Explainable AI, or XAI, is different. It shows its reasoning. It provides confidence scores. It traces data lineage from source to recommendation. It allows operators to validate assumptions before committing resources.
Here's what that looks like in practice.
An AI system predicts that accounts receivable days will drop from 45 to 32 if you implement automated insurance verification across all locations. Without explanation, your CFO is skeptical. Too many failed tech pilots. Too many vendor promises that didn't deliver.
With XAI, the system shows its work step by step. It maps current bottlenecks in your verification process. It identifies which claim types have the longest delays. It projects impact by location based on historical patterns from similar implementations. It provides confidence intervals around the prediction.
Your CFO can now validate every assumption. The projection becomes credible. The tool gets deployed across all locations with full buy-in. A/R days actually drop to 33 within 90 days. Cash flow improves. EBITDA margin expands.
That credibility drives valuation multiples when PE firms evaluate your organization.
The Valuation Impact of Transparent Decision-Making
When a private equity firm evaluates a DSO for acquisition or recapitalization, they examine operational maturity closely. A DSO that can demonstrate AI-driven margin improvement with transparent, data-backed decision-making commands a premium multiple.
As Gareth Petsch, Managing Director of pH Partners, explains, the tech stack is one of many diligence items investors review. High levels of standardization and consistency across the platform are considered best-in-class and receive favorable outcomes. A lack of clarity and standardization, especially in data systems, can delay or even derail M&A transactions.
XAI provides that clarity. It shows investors that your margin improvements aren't lucky breaks or temporary gains. They're systematic, repeatable, and scalable across the entire platform.
RSM makes this point directly. Standardization and building efficiencies through technology is generally the first place they look to help clients build enterprise value accretion.
🚀 Click here Unlock the Dental CMO Co-Pilot GPT and point it at your biggest challenge today
Building Your XAI Strategy in Seven Days
You don't need six months to start seeing value from explainable AI. Here's a practical seven-day framework to identify your highest-impact opportunities.
Day 1: Audit your current AI tools.
List every system making automated decisions or recommendations. Include marketing attribution, scheduling optimization, revenue forecasting, and patient risk scoring.
Day 2: Identify your black boxes. For each AI tool, ask:
Can your CFO validate the logic behind this recommendation?
Can we validate the underlying data? Do we understand the confidence level?
Document which systems fail these tests.
Day 3: Prioritize by EBITDA impact.
Focus first on AI tools affecting accounts receivable, labor costs, marketing ROI, or patient acquisition cost. These directly influence the metrics PE firms examine during diligence.
Day 4: Contact your vendors. Ask specific questions about explainability capabilities.
Can they provide SHAP values for predictions?
Do they offer confidence scoring?
Can they trace data lineage?
Can you override recommendations when local knowledge conflicts with AI output?
Day 5: Run a pilot test.
Pick one high-impact use case.
Implement XAI techniques on a single decision point.
Document the transparency improvement and any operational changes that result.
Day 6: Measure trust and adoption.
Survey the team using the AI tool.
Has transparency increased their confidence?
Are they more willing to act on recommendations?
Track actual implementation rates before and after adding explainability.
Day 7: Build your business case.
Calculate the EBITDA impact if you scale the transparent AI approach across all locations.
Present this to leadership with clear metrics on confidence improvement, adoption rates, and projected margin expansion.
What This Means for 2026 and Beyond
Looking ahead, experts anticipate a rebound in dental M&A activity in 2026. Now is the time to prepare your organization for that opportunity.
You need to cultivate strong organizational culture, foster positive relationships with affiliated doctors, and leverage technology for operational efficiency and growth. But you also need to demonstrate that efficiency with transparent data, not promises.
The strongest demand will be for practices and groups with EBITDA in the $1 million to $5 million range, according to TUSK Practice Sales projections for 2025. The most significant gains in valuation will come for practices exceeding $1 million in EBITDA that can show systematic margin improvement.
Groups with year-over-year EBITDA growth attract strong interest from buyers. Those experiencing declines require special buyers willing to bet on turnaround potential. Explainable AI helps you become the former, not the latter.
🎯 Let the Dental CMO Co-Pilot GPT audit your funnel and show you where to it fix first
Your Next Move
The market recalibration isn't temporary. Interest rates may stabilize, but the focus on operational efficiency and same-store growth is permanent. AI spending on margin expansion isn't stopping. But most groups can't explain where the money went or what changed.
The question is whether your AI decisions are transparent enough to build trust, scale adoption, and prove value to investors.
Start with one high-impact use case. Demand explainability from your vendors. Build internal capability to validate AI outputs. Document your wins in language PE firms understand.
Your EBITDA multiple depends on it.
Comment "transparency" and I'll send you a one-page XAI evaluation checklist for vetting your current AI tools.
Ready to build a systematic approach to AI-driven margin expansion? Book a 15-minute pilot scoping call: Let's Talk Now!
Sources:
- Planet DDS 2025 Dental Industry Outlook
- TUSK Practice Sales Market Analysis
- Dykema DSO Industry Group M&A Report
- Barclay Hill Partners Investment Thesis
- pH Partners Due Diligence Framework
- RSM Enterprise Value Research
#DSO #EBITDA #ExplainableAI #DentalMA #PrivateEquity #MarginExpansion #SameStoreGrowth
Are you tired of your marketing not working, Let's talk now! Click the link. Quick Meeting
Get the breakdown in your inbox. Join the Marketing+GenAI Power Brief Today!
📲 Check out our website: NuParadym
🎥 Get more info from our YouTube Channel: NuParadym YouTube
📲DSO Marketing X Website: DSOMarketingX
📲NXST LEAP Academy: NXST LEAP Academy
About the Author
